Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Compliance and regulatory

FDA Issues Final Guidance on Transferring 510(k) Clearances Between Device Companies

FDA issued final guidance on 20 November 2026 setting out what a new 510(k) holder must do when a device clearance is sold or transferred.

Published 20 Nov 2026· 7 minute read
A technician in a white coat works at a biosafety cabinet in an FDA life sciences laboratory in Silver Spring, Maryland
Photo: The U.S. Food and Drug Administration / Wikimedia Commons, Public domain (cropped). Source

The US Food and Drug Administration published its final guidance on transferring a 510(k) clearance from one holder to another on 20 November 2026, setting out when the buyer of a cleared device must file a new 510(k), register, list and update labelling. It matters to device companies, university spinouts and research offices that license or sell cleared medical technology.

What happened

FDA announced the availability of the final guidance “Transfer of a Premarket Notification (510(k)) Clearance – Questions and Answers” in a Federal Register notice dated 20 November 2026 under docket FDA-2024-D-1528. The document is issued jointly by the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER), and its title page reads “Document issued on November 20, 2026”. The draft was issued on 5 June 2025 (90 FR 23937).

The notice says FDA considered the comments it received on the draft and revised the guidance as appropriate, “including clarifying terminology and further explaining 510(k) holder requirements”. The guidance is nonbinding: it describes FDA’s current thinking, establishes no rights for any person and allows an alternative approach that satisfies the applicable statutes and regulations. It applies to both the previous and the new holder after a clearance for a specific device is sold or transferred.

Key details of the guidance

The guidance is written as twelve questions and answers. The points a regulatory or technology transfer team is most likely to need are these.

  • No new 510(k) for an unchanged device. When a clearance is sold or transferred and the device is not significantly changed in design, components, method of manufacture or intended use, the new holder does not need to submit a new 510(k), because it is not proposing to begin introducing the device into interstate commerce. If the new holder has significantly changed or modified the device, it must generally submit a new 510(k).
  • One holder at a time. FDA treats there as being a single 510(k) holder for a device at any time. The guidance gives the reasons as compliance with legal requirements, tracking of signals and adverse events, and communication between sponsors and FDA. It says it is not meant to limit anyone’s ability to transfer a 510(k) or to enter business arrangements.
  • Registration and listing. A new holder engaged in activities that require listing must list the device in FDA’s electronic registration and listing system under 21 CFR 807.25. If it has not previously entered into a regulated operation, it must register within 30 days of doing so and submit listing information, including the FDA-assigned premarket submission number. The system assigns a new unique listing number when the new holder creates the listing.
  • Which number to enter. For an unchanged device the new holder enters the original FDA-assigned premarket submission number. Contract manufacturers, contract sterilisers, repackagers and relabelers that must list the device also use the 510(k) holder’s number.
  • Labelling and UDI. A transfer may require label updates, including the name and place of business of the manufacturer, packer or distributor. Where information such as the labeler name changes, the labeler must update the Global Unique Device Identification Database (GUDID).
  • Consequences. The guidance states that a device may be considered adulterated or misbranded if a firm fails to register, list, update GUDID information or submit a required marketing application.
  • Who updates FDA. FDA says it commonly receives notifications from individuals who hold a transferred clearance, but that the responsibility rests with the owner or operator of the establishment, and FDA is not required to update registration or listing information in response to such notifications.

Background and context

A 510(k) is the premarket notification a manufacturer files to show that a device is substantially equivalent to a legally marketed predicate device. The guidance defines the 510(k) clearance as FDA’s order declaring the device substantially equivalent, and the 510(k) holder as the single person who possesses the clearance. The applicant named in the public 510(k) database does not change when a clearance is transferred, so the database alone does not show the current holder; casrai explains the database in its guide to FDA 510(k) data.

Why the listing matters: FDA points to its registration and listing system as the way it identifies who makes or processes a device, including for postmarket surveillance work such as promptly notifying a firm that it must begin a recall. A transfer that is not reflected in the listing leaves FDA, and anyone relying on its records, looking at the wrong company.

For readers new to the pathway, casrai has background on the 510(k) premarket notification, on how the K number identifies a clearance, on how the route differs in the 510(k) versus De Novo comparison, and on the wider device classification and pathway rules.

Reaction to the draft

Hogan Lovells, which analysed the draft in June 2025, described it as a guidance that does not expand or contract FDA authority but that highlights the rationale for timing and communication of 510(k) transfers, and noted that a labeler must meet UDI requirements, including having the UDI on the label before commercial distribution.

RAPS reported on 6 August 2025 that medtech trade groups had asked FDA for significant changes. The Medical Device Manufacturers Association asked for a retitling to refer to a cleared 510(k), for definitions consistent with those on FDA’s website, and for FDA to state that a manufacturer that acquires a 510(k) may use it as a predicate in a Special 510(k). It argued that several innovators who collaborate on a device might each want their own 510(k), asked how disputes over a claimed clearance would be handled, and warned that treating labelling lapses on acquired finished stock as misbranding could cause device shortages during asset sales. It recommended flexibility for orderly technology, business or IP transfers that maintain patient access.

AdvaMed asked FDA to clarify that the new holder receives a new listing number and that a clearance sold before the device is in commercial distribution would not require a redundant new filing.

The final text keeps the single-holder position and says that case-specific questions about who the holder is should go to FDA’s 510(k) staff. Its answer on new 510(k) filings rests on whether the new holder would be proposing to begin introducing the device into interstate commerce.

What it means for researchers, universities and research offices

Universities rarely hold 510(k) clearances themselves, but many technology transfer offices license university-developed device technology to startups and established companies, and spinouts are frequent buyers and sellers of cleared products. This section is editorial interpretation of the guidance for that audience.

  • Licence and acquisition agreements. The guidance does not limit how a clearance may be transferred, but it places registration, listing, labelling and GUDID duties on the new holder and listing updates on the previous one. Deal timetables for a spinout sale or a licensee’s acquisition of a cleared product should allow for the 30-day registration window and the label changes the guidance describes.
  • Single holder. Because FDA recognises one holder per device, collaboration, co-development and sublicensing arrangements need to state which party holds the clearance and which parties list the device using its number.
  • Design changes after transfer. A buyer that plans to significantly change design, components, manufacturing method or intended use should plan for a new 510(k) rather than rely on the transferred one.
  • Records. The prior owner is the first source for the clearance file, so transfer agreements should provide for handing over 510(k) documents; the alternative the guidance names is a FOIA request.
  • Clinical investigators and sponsors. Researchers who use or study a cleared device should confirm the current holder through the listing rather than the 510(k) database applicant name, since the two can differ after a transfer.

What happens next

The guidance is final, and FDA accepts comments on any guidance at any time through the docket, FDA-2024-D-1528 on regulations.gov, although it notes that comments may not be acted on until the document is next revised. FDA lists a document number, GUI00001808, for requests for copies, and its 510(k) staff handle case-specific questions about transfers.

Sources

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →